Middle aged woman dressed in pink showing strength and smiling in a park. Fight against breast cancer.
getty
A recently developed targeted cancer drug could offer a more effective initial treatment for a particularly aggressive type of breast cancer. An extensive international clinical trial showed that patients treated with this drug lived longer and experienced twice the duration before their cancer progressed compared to those undergoing standard chemotherapy. Additionally, this treatment frequently led to tumor reduction and sustained responses.
Triple-negative breast cancer represents approximately 10% to 20% of all breast cancer cases. Unlike other types of breast cancer, it lacks the typical targets necessary for hormone therapies and other precision medicines to be effective. This cancer type tends to spread rapidly, recur early, and is challenging to treat once it metastasizes.
For many individuals, chemotherapy is the primary treatment. While immune-based therapies have improved results for some, most patients with advanced triple-negative breast cancer are not suitable candidates for these treatments. Consequently, there is increasing interest in therapies that deliver potent cancer drugs more precisely, bypassing some limitations of traditional chemotherapy.
A Guided Delivery System
This new treatment is part of a growing category of medications known as antibody-drug conjugates, which pair a targeting antibody with a chemotherapy drug.
The antibody functions like an address label, identifying a specific protein that is prevalent on many breast cancer cells and binding to it. Once connected, the cancer cell absorbs the drug and releases the chemotherapy precisely where it is needed.
Traditional chemotherapy circulates throughout the body, affecting both cancerous and healthy cells. Antibody-drug conjugates offer a more targeted approach, concentrating treatment within tumor cells, which allows for potent chemotherapy delivery while minimizing exposure to healthy cells.
This method has already changed the treatment landscape for several cancers, including some breast cancers. The recent trial suggests it could also enhance outcomes when used as an initial treatment for advanced triple-negative breast cancer.
Why Triple-Negative Breast Cancer Remains Challenging
Triple-negative breast cancer is often more aggressive than other types, spreading earlier and being more likely to recur after treatment.
When the cancer spreads beyond the breast, the challenge intensifies. Patients often have few treatment options, and chemotherapy responses are typically short-lived.
Approximately 70% of patients with advanced triple-negative breast cancer are not eligible for immune-based therapies. For these patients, chemotherapy remains the primary treatment despite its limited effectiveness and durability.
Finding a treatment that can manage the disease longer without significantly increasing severe side effects would fill a crucial gap.
What the Trial Found
More than 640 patients with advanced triple-negative breast cancer participated in the trial, none of whom were eligible for immune-based therapy.
Those receiving the targeted drug experienced an average of almost 11 months before their disease progressed, compared to just under 6 months for those on chemotherapy.
The targeted drug also enhanced overall survival, with patients living nearly 2 years on average, compared to about one and a half years for chemotherapy recipients.
Tumor reduction was significantly more frequent with the targeted therapy, with nearly two-thirds of patients experiencing shrinkage, compared to less than one-third on chemotherapy. Tumor responses lasted longer, averaging over a year, and some patients even saw a complete disappearance of detectable tumors on imaging scans.
Side Effects Remained Manageable
Though no cancer treatment is without side effects, the new drug presented its own set of challenges. The most common side effects included mouth sores, nausea, and hair loss. Most mouth and eye-related issues were mild to moderate and could typically be managed without halting treatment.
Serious side effects related to treatment occurred at similar rates in both groups. Notably, fewer patients discontinued treatment due to side effects with the targeted drug compared to chemotherapy, and no treatment-related deaths were reported during the trial.
A Potential Shift in Treatment
The findings contribute to the growing body of evidence that guided chemotherapy delivery systems can surpass traditional chemotherapy in treating aggressive cancers.
The benefits extended beyond tumor shrinkage, as patients lived longer, remained progression-free for longer, and could continue treatment for much longer periods.
The results also highlight the significance of a specific cell-surface protein found on many triple-negative breast cancer cells, which is becoming an increasingly important target for new cancer treatments.
For patients unable to receive immune-based therapies, this advancement may represent a clear improvement. A disease historically characterized by few treatment options might soon have a more effective initial alternative.
This work is part of a series showcasing how modern antibody strategies can be harnessed to boost immune responses, with potential applications across various diseases and therapeutic areas.
